Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Metronomic Temozolomide for Recurrent Malignant Glioma
NCT00501891Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, temozolomide in glioblastoma multiforme (GBM), sponsored by Duke University. Started Jul 2007; status: completed.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00501891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501891.